Oscient Pharmaceuticals Announces Management Change
Advertisement
Oscient Pharmaceuticals Corporation announced that Dominick Colangelo has resigned to pursue another employment opportunity. Subsequently, the Oscient corporate officer team will include Steve Rauscher, CEO and President; Philippe Maitre, EVP and Chief Financial Officer; and Mark Glickman, SVP, Sales and Marketing.
Mr. Colangelo will provide business development consulting services to Oscient through January 31, 2009, with the potential for extension. He will be entitled to consulting fees, as well as an incentive for completion of certain business development objectives.
Anthony Watkins, Vice President of Corporate Development, will direct all business development efforts and will now report to Mr. Rauscher.